Rezultati pretraživanja
  1. 31. sij

    The genealogy of CAR-Ts. Excellent overview of new updates on CARTs by Carl June Nice to see more sophisticated genome editing starting to play a role

    1 reply 17 proslijeđenih tweetova 37 korisnika označava da im se sviđa
  2. 2. velj

    ⚡️ “” my coverage with 50 presentations from the 2nd European CAR T Meeting, Sitges / Barcelona, Spain (S. Riddell, C. June, M. Sadelain, C. McKall, K. Revzani, M. Pule, M. Van den Brinck, B. Levine, G. Salles, C. Thieblemont, H. Einsele, etc)

    13 proslijeđenih tweetova 25 korisnika označava da im se sviđa
  3. 1. velj

    Bruce Levine - next ISCT President - illustrating different organizational models for cellular therapy manufacturing. Stresses the need for comparative studies in these simulations. ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩

    1 reply 3 proslijeđena tweeta 9 korisnika označava da im se sviđa
  4. 1. velj

    Steep road ahead ⁦⁩ ⁦⁩

    1 proslijeđeni tweet 4 korisnika označavaju da im se sviđa
  5. 1. velj

    Important to support patients in this situation

    So important to think about those many patients who can’t or don’t have a CAR. ‘CAR-T ineligible what now?’ Fantastic round of talks in this mornings nurses session
    3 proslijeđena tweeta 11 korisnika označava da im se sviđa
  6. 1. velj

    S Mielke (Sweden) Karolinska 2/x burning questions mixed feeling, 1st patient in Sweden (Uppsala) treated in 2014 translation is one thing, implementation is even harder

    1 reply 2 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  7. 1. velj

    Following the conference by online streaming this morning. Very interesting round table on management of side effects

    1 korisnik označava da mu se sviđa
  8. 1. velj

    shows us the concerns unique to the CAR T population. We continue on the theme of managing expectations and strategies of communicating during difficult conversations.

    1 proslijeđeni tweet 4 korisnika označavaju da im se sviđa
  9. 1. velj

    Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in

    18 proslijeđenih tweetova 46 korisnika označava da im se sviđa
  10. 31. sij

    I Avivi - CAR T Experience in DLBCL 4/x

    1 reply 1 proslijeđeni tweet 1 korisnik označava da mu se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  11. 31. sij

    BJ Verhoeven - A joint effort: Patients' perspective 5/x

    1 reply 3 proslijeđena tweeta 7 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  12. 31. sij

    M Schüssler-Lenz (EMA CAT chair) - Marketing authorization for CAR T cells - The EMA perspective 5/x => these differences have to support a therapeutic effect the plan must be discussed during scientific advice procedures conclusion new EMA guidelines

    2 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  13. 31. sij

    S Guedan Carrio - Improving CAR T cells in solid tumors 1/x

    1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  14. 31. sij

    Dr Berger: Digital PCR for quantification of commercial CAR T products

    1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
  15. 31. sij

    Car-T pipeline at , some licensed to , others not

    1 reply 3 proslijeđena tweeta 9 korisnika označava da im se sviđa
  16. 31. sij

    Another of those comparison slides we all love. Auto1 in adult ALL vs , via Martin Pule

    5 proslijeđenih tweetova 15 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  17. 31. sij

    explains that 4-1BB signalling induces mitochondrial , whereas CD28 induces in .

    1 proslijeđeni tweet 6 korisnika označava da im se sviđa
  18. 31. sij

    Japanese team's discovery of integrin β7 as target in MM in 2017 moving into the CAR T space

    5 korisnika označava da im se sviđa
  19. 30. sij

    CONGRESS | | D Madduri presents data from CARTITUDE study in R/R multiple patients.

    6 proslijeđenih tweetova 19 korisnika označava da im se sviđa
  20. 30. sij

    Martin Pule takes us through the UCL CAR T programme at the EHA/EBMT meeting at Sitges. Really promising early data from use of AUTO1 in ALLCAR19 adult study wrt tox/persistence/DOR. A look to the future of next gen CAR T studies - watch this space!

    14 proslijeđenih tweetova 24 korisnika označavaju da im se sviđa

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.